The News
Profound Medical Corp. will host an investor call on March 13 to discuss the first clinical outcomes from the CAPTAIN trial, comparing the TULSA Procedure™ to robotic radical prostatectomy for localized prostate cancer. The results will be presented during a high-impact session at an upcoming medical conference.
Why It Matters
The outcomes from the CAPTAIN trial could validate the efficacy and safety of AI-powered, incision-free therapies in prostate cancer treatment, potentially influencing future medical practices and investment in AI-driven healthcare solutions. This aligns with the growing trend of integrating AI into medical procedures, enhancing patient outcomes and operational efficiencies.
Key Evidence
The information is sourced from an official announcement by Profound Medical Corp., reported by GLOBE NEWSWIRE, indicating a reliable reporting channel.